Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$123.50
-3.00 (-2.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-165.7M · quality 70.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-50.6%
↓Gross Margin
64.3%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+180.9%
FCF CAGR
—
FCF margin
-2497.5%
FCF / Net income
0.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.4M · net income $-214.4M · FCF $-210.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $8.4M | $8.4M | — | $1.1M |
| Net Income | $-214.4M | $-214.4M | $-167.4M | $-120.7M |
| EBITDA | $-205.2M | $-205.2M | $-159.5M | $-111.5M |
| EPS | — | — | -3.69 | -3.12 |
| Gross Margin | 64.3% | 64.3% | — | -6.8% |
| Operating Margin | -2617.6% | -2617.6% | — | -11620.3% |
| Net Margin | -2549.3% | -2549.3% | — | -11321.1% |
| Balance Sheet | ||||
| Debt/Equity | 0.03 | 0.03 | 0.03 | 0.10 |
| Current Ratio | 35.74 | 35.74 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-210.0M | $-210.0M | $-165.7M | $-107.1M |
| Returns | ||||
| ROE | -50.6% | -50.6% | -32.4% | -58.4% |
| Valuation | ||||
| P/B | 15.26 | 15.26 | 4.35 | — |
| Growth & Yield | ||||
| EPS Growth | — | — | -18.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+110.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.69 → n/d
Residual
+110.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.